The Preeclampsia Foundation and its affiliate Preeclampsia Foundation Canada have announced that Nga Ling Ko, PhD, and Sruthi Alahari, PhD, are recipients of the 2018 Vision Grants. These highly competitive monetary awards recognize the best young investigators with novel research ideas in preeclampsia and related hypertensive disorders of pregnancy. Ko was awarded $19,000 USD and Alahari was awarded $19,500 CAD.
The Vision Grants were awarded to the scientific proposals recommended by the Preeclampsia Foundation’s scientific review committee with a further review by a consumer advisory board. The Preeclampsia Foundation’s Board of Directors from the US and Canada rendered the final decision on those recommendations.
Dr. Ko’s research, “Piezo1 Mechanotransduction in the Gestational Uterine Circulation,” will be conducted at The University of Vermont (UVM) in Burlington. The purpose of this study is to understand maternal uterine vascular adaptation during pregnancy – a mechanism that is essential for facilitating the progressive increases in uteroplacental flow that are required for normal fetal growth and development.
“It is my strength to coordinate and bring together the expertise of different people and facilities,” said Ko. “The project combines my previous and present research trainings, expertise on reproductive medicine in our department, and collaborations with core facilities at UVM to understand the role of Piezo1 mechanotransduction in the uterine circulation in normal versus preeclamptic pregnancies, which is a novel and previously unrecognized area in the field.”
Ko earned her PhD in Pharmacology at The Chinese University of Hong Kong and currently serves as Postdoctoral Fellow at the Department of Obstetrics, Gynecology and Reproductive Sciences, College of Medicine, The University of Vermont. She has co-authored numerous publications and presentations, and provided extensive research support since her graduate studies at The Chinese University of Hong Kong.
Dr. Alahari’s study, “Towards Understanding Placental FN Processing in Preeclampsia and its Utility as an Early Predictor,” will be conducted at Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
“Emerging research implicates small carriers called exosomes, particularly those of placental origin, in transmitting information on health status during pregnancy,” said Alahari. Exosomes are cell-derived vesicles that are present in many and perhaps all eukaryotic fluids, including blood, urine, and cultured medium of cell cultures. “This study will extract placental exosomes through pregnancy, measure their content, and monitor whether abnormal exosome profiles can be linked to the development of preeclampsia.
“I decided to devote my career to research in the field of preeclampsia due to the fact that my younger sister is severely affected by cerebral palsy because our mother experienced preeclampsia during her pregnancy.”
Alahari earned a Medical Degree at the University of Siena in Italy and PhD at the University of Parma, also in Italy. Alahari currently serves as Senior Scientist and Professor at Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital. Alahari has received numerous awards and scholarships, and co-authored a host of presentations and scientific abstracts.
For more information or to arrange an interview with these Vision Grant recipients or the leadership of the Preeclampsia Foundation and/or Preeclampsia Foundation Canada, please call 1.800.665.9341.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
While the Preeclampsia Foundation has been championing patient advocacy and representation for all families affected by hypertension in pregnancy throughout our 25 year history, we recognized the uniq...
Genetic predictors of blood pressure traits are associated with preeclampsia Although underlying causes of preeclampsia are not fully understood, there is evidence suggesting a strong genetic compone...
Hypertensive disorders of pregnancy (HDP) are a leading cause of maternal mortality and can put both mother and baby at risk for problems during pregnancy. Women who had HDPs have postpartum risk...
Elevated Blood Pressure in Pregnancy and Long-Term Cardiometabolic Health Outcomes This study looked at how elevated blood pressure during the third trimester of pregnancy affects cardiometabolic hea...
Planned early-term delivery in individuals with mild chronic hypertension was not associated with a reduction in adverse maternal outcomes but was associated with an increase in some neonatal complica...